X4 Pharmaceuticals Inc (XFOR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.07-5.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · XFOR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
7 Mavorixafor: An Oral Agent Designed to Alleviate Neutropenia Targeted Mechanism • CXCR4 regulates movement of white blood cells throughout the body2 • CXCR4 antagonism results in the migration of w…
Stated in 1 of 1 supplied quarters. Management reported: “7 Mavorixafor: An Oral Agent Designed to Alleviate Neutropenia Targeted Mechanism • CXCR4 regulates movement of white blood cells throughout the body2 • CXCR4 antagonism results in the migration of white blood cells from the bone marrow3,4 Modified figure from reference1 Orally active CXCR4 Antagonist • Mavorixafor raises circulating blood levels of neutrophils and lymphocytes4,5,6,7 • Top-line pivotal Phase 3 study in Primary Chronic Neutropenia data expected in Q1 2028 • U.S. patent protection expected through 2038 Validated mechanism with the potential to increase neutrophil counts and decrease infection rates 1.” Revenue was $2.800 million in 2026-Q3.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“7 Mavorixafor: An Oral Agent Designed to Alleviate Neutropenia Targeted Mechanism • CXCR4 regulates movement of white blood cells throughout the body2 • CXCR4 antagonism results in the migration of w…”
“Our partnership with K2 HealthVentures strengthens our capital position and gives us a solid financial foundation as we advance mavorixafor toward potential FDA approval and a commercial launch in c…
Stated in a supplied disclosure. Management reported: ““Our partnership with K2 HealthVentures strengthens our capital position and gives us a solid financial foundation as we advance mavorixafor toward potential FDA approval and a commercial launch in chronic neutropenia,” said David Kirske, Chief Financial Officer of X4.” “The new K2HV facility provides a larger total facility size, a longer interest-only period, and a 48-month maturity to support corporate activities, including the potential future commercial launch of mavorixafor in chronic neutropenia.”
7 Mavorixafor: An Oral Agent Designed to Alleviate Neutropenia Targeted Mechanism • CXCR4 regulates movement of white blood cells throughout the body2 • CXCR4 antagonism results in the migration of w…
Stated in 1 of 1 supplied quarters. Management reported: “7 Mavorixafor: An Oral Agent Designed to Alleviate Neutropenia Targeted Mechanism • CXCR4 regulates movement of white blood cells throughout the body2 • CXCR4 antagonism results in the migration of white blood cells from the bone marrow3,4 Modified figure from reference1 Orally active CXCR4 Antagonist • Mavorixafor raises circulating blood levels of neutrophils and lymphocytes4,5,6,7 • Top-line pivotal Phase 3 study in Primary Chronic Neutropenia data expected in Q1 2028 • U.S. patent protection expected through 2038 Validated mechanism with the potential to increase neutrophil counts and decrease infection rates 1.” “Semin Hematol. 2013; Dale DC, SCNIR publications.”
“7 Mavorixafor: An Oral Agent Designed to Alleviate Neutropenia Targeted Mechanism • CXCR4 regulates movement of white blood cells throughout the body2 • CXCR4 antagonism results in the migration of w…”
Develop mavorixafor for primary chronic neutropenia through the pivotal 4WARD study and planned follow-on clinical work.
Finish enrolling patients in the global Phase 3 4WARD trial for mavorixafor in chronic neutropenia by year-end 2026.
Over the trailing year it converted -6.77x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 34% of the time over the next year (vs 53% for the rest of the cohort, n=2525).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.